Hello Heart, an Israel-based medical monitoring technology developer backed by automotive components manufacturer Wanxiang, has raised $12m in funding, VentureBeat reported on Tuesday.
The round was led by venture capital firm Khosla Ventures and also featured fellow VC firms BlueRun Ventures, Maven Ventures and Resolute Ventures.
Hello Heart is the creator of an in-home blood pressure monitor that allows users to self-manage hyperextension.
The company’s mobile app keeps track of users’ blood sugar, weight and activity, offering personalised advice on how to manage conditions like diabetes and stress based on automatically imported laboratory results.
Maayan Cohen, chief executive of Hello Heart, told VentureBeat the capital will be used to expand its sales staff. The company raised $9m in a January 2018 round led by BlueRun that included Wanxiang Healthcare Investments, the healthcare-focused venture fund backed by Wanxiang.
Maven Ventures, Arba Ventures, Amicus Ventures, Arab Angel Fund, Franklin Trust and Resolute Ventures also took part in the 2018 round. Resolute had already led a $1.3m round for the company in 2015 that also featured private investors Noam Bardin, John Malloy and Ran Makavy.